ASCENDIS PHARMA A/S - ADR (ASND) Forecast, Price Target & Analyst Ratings

NASDAQ:ASND • US04351P1012

223.82 USD

-3.59 (-1.58%)

At close: Mar 19, 2026

223.82 USD

0 (0%)

After Hours: 3/19/2026, 6:44:15 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ASCENDIS PHARMA A/S - ADR (ASND).

Consensus Price Target

Price Target

$289.23

+ 29.23% Upside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: Apr 29, 2026
Period: Q1 / 2026
EPS Estimate: €0.39
Revenue Estimate: 287.1M

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

88.33%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$289.23

Upside

+ 29.23%

From current price of $223.82 to mean target of $289.23, Based on 24 analyst forecasts

Low

$247.45

Median

$277.44

High

$359.10

Price Target Revisions

1 Month

4.10%

3 Months

8.62%

Price Target Summary

24 Wall Street analysts provided a forecast for the next 12 months for ASND. The average price target is 289.23 USD. This implies a price increase of 29.23% is expected in the next year compared to the current price of 223.82.

The average price target has been revised upward by 8.62% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

88.33%

ASND was analyzed by 24 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about ASND.

In the previous month the buy percentage consensus was at a similar level.

ASND was analyzed by 24 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2026-03-03	RBC Capital	Maintains	Outperform -> Outperform
2026-02-12	Oppenheimer	Maintains	Outperform -> Outperform
2026-02-12	Wedbush	Maintains	Outperform -> Outperform
2026-01-30	B of A Securities	Maintains	Buy -> Buy
2026-01-28	Barclays	Initiate	Overweight
2026-01-20	RBC Capital	Maintains	Outperform -> Outperform
2026-01-20	Wells Fargo	Maintains	Overweight -> Overweight
2026-01-09	Wells Fargo	Maintains	Overweight -> Overweight
2026-01-07	TD Cowen	Reiterate	Buy -> Buy
2025-12-11	Stifel	Maintains	Buy -> Buy
2025-11-18	Wedbush	Reiterate	Outperform -> Outperform
2025-10-17	Raymond James	Initiate	Strong Buy
2025-10-13	Cantor Fitzgerald	Maintains	Overweight -> Overweight
2025-10-09	JP Morgan	Maintains	Overweight -> Overweight
2025-09-02	B of A Securities	Maintains	Buy -> Buy
2025-08-19	JP Morgan	Maintains	Overweight -> Overweight
2025-08-08	Cantor Fitzgerald	Maintains	Overweight -> Overweight
2025-08-08	UBS	Maintains	Buy -> Buy
2025-08-08	RBC Capital	Maintains	Outperform -> Outperform
2025-08-08	Stifel	Maintains	Buy -> Buy
2025-08-08	Wedbush	Maintains	Outperform -> Outperform
2025-08-08	Wells Fargo	Maintains	Overweight -> Overweight
2025-08-08	Citigroup	Maintains	Buy -> Buy
2025-07-29	JP Morgan	Maintains	Overweight -> Overweight
2025-07-11	Citigroup	Maintains	Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date: Apr 29, 2026
Period: Q1 / 2026
EPS Estimate: €0.39
Revenue Estimate: 287.1M
Revenue Q2Q: 184.39%
EPS Q2Q: 125.00%
Number of Analysts: 17

Next Earnings Revisions

Revenue (1 Month)

2.38%

Revenue (3 Months)

3.81%

EPS (1 Month)

6.38%

EPS (3 Months)

23.21%

Next Earnings Summary

ASND is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is 0.39 USD and the consensus revenue estimate is 287.10M USD.

The next earnings revenue estimate has been revised upward by 3.81% in the past 3 months.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Revenue YoY % growth	266.718M 421.24%	363.641M 36.34%	720.132M 98.03%	1.426B 98.02%	2.041B 43.13%	2.524B 23.66%	3.035B 20.25%	3.399B 11.99%	3.512B 3.32%	3.79B 7.92%	3.98B 5.01%
EBITDA YoY % growth	-428.796M 21.16%	-261.049M 39.12%	-118.575M 54.58%	451.15M 480.48%	911.08M 101.95%	1.655B 81.65%	N/A	N/A	N/A	N/A	N/A
EBIT YoY % growth	-447.707M 20.31%	-278.763M 37.74%	-136.271M 51.12%	338.47M 348.38%	743.69M 119.72%	1.155B 55.31%	1.457B 26.15%	1.73B 18.74%	1.66B -4.05%	1.852B 11.57%	1.971B 6.43%
Operating Margin	-167.86%	-76.66%	-18.92%	23.74%	36.44%	45.76%	48.01%	50.90%	47.27%	48.87%	49.52%
EPS YoY % growth	-8.56 17.69%	-6.57 23.25%	-3.77 42.62%	4.80 227.33%	11.05 130.30%	16.41 48.47%	22.52 37.19%	26.10 15.89%	25.62 -1.81%	27.83 8.61%	29.38 5.57%

All data in EUR

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26
EPS Q2Q % growth	0.39 125.00%	0.81 225.92%	0.75 175.17%	1.36 348.10%
Revenue Q2Q % growth	287.1M 184.39%	329.31M 108.36%	347.08M 62.46%	399.53M 61.43%
EBITDA Q2Q % growth	44.407M 148.19%	87.979M 299.51%	58.135M 143.56%	N/A
EBIT Q2Q % growth	33.812M 134.96%	68.206M 228.81%	73.536M 568.69%	110.89M 1,020.55%

All data in EUR

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

85.22%

EPS Next 5 Year

54.92%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

51.26%

Revenue Next 5 Year

36.05%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

144.27%

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ASCENDIS PHARMA A/S - ADR / ASND Forecast FAQ

What do analysts expect the price target to be for ASCENDIS PHARMA A/S - ADR (ASND)?

24 analysts have analysed ASND and the average price target is 289.23 USD. This implies a price increase of 29.23% is expected in the next year compared to the current price of 223.82.

What is the next earnings date for ASND stock?

ASCENDIS PHARMA A/S - ADR (ASND) will report earnings on 2026-04-29, after the market close.

What are the consensus estimates for ASND stock next earnings?

The consensus EPS estimate for the next earnings of ASCENDIS PHARMA A/S - ADR (ASND) is 0.39 USD and the consensus revenue estimate is 287.10M USD.

What is the expected long term growth rate for ASCENDIS PHARMA A/S - ADR (ASND)?

The expected long term growth rate for ASCENDIS PHARMA A/S - ADR (ASND) is 51.26%.

Analyst forecast overview

Forecast Snapshot